Dr. Michael Vazquez obtained his Ph.D. at Northwestern University. After a 2-year Postdoc at the Research Triangle Institute, he began his career in Pharma as a medicinal chemist. He later became a Director and Associate Research Fellow at Pfizer. He was the chemistry lead for Pfizer’s JAK3 inhibitor program prior to taking the project led for Pfizer's selective JAK1 program leading to the recently approved JAK1i Cibinqo. Early in his career he discovered the sulfonamide class of HIV protease inhibitors which lead to the successful commercial development of three HIV drugs Angenerase, Lexiva and Prezista. Dr. Vazquez also served as a chemistry group leader while working on cMet kinase in partnership with Sugen Pharma. This project led to the development of Xalkori a cMet/ALK inhibitor for NSCLC. Dr. Vazquez joined Lynk Pharmaceuticals as a co-founder and head of chemistry. He has contributed to the discovery of four clinical candidates with 3 currently in human clinical trials. He is a co-inventor on over 130 US patents and >340 foreign filings and coauthor on 23 peer reviewed publications. Dr. Vazquez has served as reviewer for scientific journals and has lectured at numerous conferences and universities.